These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

710 related items for PubMed ID: 11502611

  • 1. Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls.
    Young-Min SA, Beeton C, Laughton R, Plumpton T, Bartram S, Murphy G, Black C, Cawston TE.
    Ann Rheum Dis; 2001 Sep; 60(9):846-51. PubMed ID: 11502611
    [Abstract] [Full Text] [Related]

  • 2. Relationship between matrix metalloproteinases/tissue inhibitors of matrix metalloproteinases systems and autoantibody patterns in systemic sclerosis.
    Montagnana M, Volpe A, Lippi G, Caramaschi P, Salvagno GL, Biasi D, Bambara LM, Guidi GC.
    Clin Biochem; 2007 Aug; 40(12):837-42. PubMed ID: 17493602
    [Abstract] [Full Text] [Related]

  • 3. Clinical significance of serum levels of matrix metalloproteinase-13 in patients with systemic sclerosis.
    Asano Y, Ihn H, Kubo M, Jinnin M, Mimura Y, Ashida R, Tamaki K.
    Rheumatology (Oxford); 2006 Mar; 45(3):303-7. PubMed ID: 16278285
    [Abstract] [Full Text] [Related]

  • 4. Serum levels of tissue inhibitor of metalloproteinases 2 in systemic sclerosis: a preliminary study.
    Dziankowska-Bartkowiak B, Waszczykowska E, Łuczyńska M, Zalewska A, Sysa-Jedrzejowska A.
    Med Sci Monit; 2002 Feb; 8(2):CR108-12. PubMed ID: 11859283
    [Abstract] [Full Text] [Related]

  • 5. Gelatinase A (MM-2), gelatinase B (MMP-9) and their inhibitors (TIMP 1, TIMP-2) in serum of women with endometriosis: Significant correlation between MMP-2, MMP-9 and their inhibitors without difference in levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in relation to the severity of endometriosis.
    Salata IM, Stojanovic N, Cajdler-Łuba A, Lewandowski KC, Lewiński A.
    Gynecol Endocrinol; 2008 Jun; 24(6):326-30. PubMed ID: 18584412
    [Abstract] [Full Text] [Related]

  • 6. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity.
    Chen CH, Lin KC, Yu DT, Yang C, Huang F, Chen HA, Liang TH, Liao HT, Tsai CY, Wei JC, Chou CT.
    Rheumatology (Oxford); 2006 Apr; 45(4):414-20. PubMed ID: 16287916
    [Abstract] [Full Text] [Related]

  • 7. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
    Ylisirniö S, Höyhtyä M, Turpeenniemi-Hujanen T.
    Anticancer Res; 2000 Apr; 20(2B):1311-6. PubMed ID: 10810441
    [Abstract] [Full Text] [Related]

  • 8. Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis.
    Klimiuk PA, Sierakowski S, Domyslawska I, Chwiecko J.
    J Rheumatol; 2004 Feb; 31(2):238-42. PubMed ID: 14760791
    [Abstract] [Full Text] [Related]

  • 9. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
    Keyszer G, Lambiri I, Nagel R, Keysser C, Keysser M, Gromnica-Ihle E, Franz J, Burmester GR, Jung K.
    J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954
    [Abstract] [Full Text] [Related]

  • 10. Elevated matrix metalloproteinase-9 in patients with systemic sclerosis.
    Kim WU, Min SY, Cho ML, Hong KH, Shin YJ, Park SH, Cho CS.
    Arthritis Res Ther; 2005 Feb; 7(1):R71-9. PubMed ID: 15642145
    [Abstract] [Full Text] [Related]

  • 11. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
    Oberg A, Höyhtyä M, Tavelin B, Stenling R, Lindmark G.
    Anticancer Res; 2000 Feb; 20(2B):1085-91. PubMed ID: 10810401
    [Abstract] [Full Text] [Related]

  • 12. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy.
    Rysz J, Banach M, Stolarek RA, Pasnik J, Cialkowska-Rysz A, Koktysz R, Piechota M, Baj Z.
    J Nephrol; 2007 Feb; 20(4):444-52. PubMed ID: 17879211
    [Abstract] [Full Text] [Related]

  • 13. Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease.
    Brunner S, Kim JO, Methe H.
    Am J Cardiol; 2010 Feb 15; 105(4):429-34. PubMed ID: 20152234
    [Abstract] [Full Text] [Related]

  • 14. Serum MMP-1 and TIMP-1 levels are increased in patients with psoriatic arthritis and their siblings.
    Myers A, Lakey R, Cawston TE, Kay LJ, Walker DJ.
    Rheumatology (Oxford); 2004 Mar 15; 43(3):272-6. PubMed ID: 14523226
    [Abstract] [Full Text] [Related]

  • 15. Significant increases in serum and plasma concentrations of matrix metalloproteinases 3 and 9 in patients with rapidly destructive osteoarthritis of the hip.
    Masuhara K, Nakai T, Yamaguchi K, Yamasaki S, Sasaguri Y.
    Arthritis Rheum; 2002 Oct 15; 46(10):2625-31. PubMed ID: 12384920
    [Abstract] [Full Text] [Related]

  • 16. Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis.
    Benesová Y, Vasku A, Novotná H, Litzman J, Stourac P, Beránek M, Kadanka Z, Bednarík J.
    Mult Scler; 2009 Mar 15; 15(3):316-22. PubMed ID: 19153173
    [Abstract] [Full Text] [Related]

  • 17. Serum levels of matrix metalloproteinase-9 and its tissue inhibitor (TIMP-1) in acute disseminated encephalomyelitis.
    Ichiyama T, Kajimoto M, Suenaga N, Maeba S, Matsubara T, Furukawa S.
    J Neuroimmunol; 2006 Mar 15; 172(1-2):182-6. PubMed ID: 16321449
    [Abstract] [Full Text] [Related]

  • 18. Matrix metalloproteinases (MMP-8, MMP-9) and the tissue inhibitors of metalloproteinases (TIMP-1, TIMP-2) in patients with fungal keratitis.
    Rohini G, Murugeswari P, Prajna NV, Lalitha P, Muthukkaruppan V.
    Cornea; 2007 Feb 15; 26(2):207-11. PubMed ID: 17251814
    [Abstract] [Full Text] [Related]

  • 19. Can CCL2 serum levels be used in risk stratification or to monitor treatment response in systemic sclerosis?
    Carulli MT, Handler C, Coghlan JG, Black CM, Denton CP.
    Ann Rheum Dis; 2008 Jan 15; 67(1):105-9. PubMed ID: 17604287
    [Abstract] [Full Text] [Related]

  • 20. Occurrence of matrix metalloproteinases and tissue inhibitors of metalloproteinases in tuberculous pleuritis.
    Hoheisel G, Sack U, Hui DS, Huse K, Chan KS, Chan KK, Hartwig K, Schuster E, Scholz GH, Schauer J.
    Tuberculosis (Edinb); 2001 Jan 15; 81(3):203-9. PubMed ID: 11466032
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.